The US Food and Drug Administration (FDA) has approved nitroglycerin ointment 0.4% (Rectiv, ProStrakan Group) for the treatment of moderate to severe pain associated with chronic anal fissures, the company announced today.
- Jun 30 Thu 2011 06:33
- Jun 28 Tue 2011 03:24
The US Food and Drug Administration (FDA) late yesterday approved the first autologous aesthetic cell therapy to improve the appearance of moderate to severe nasolabial fold wrinkles in adults.
- Jun 26 Sun 2011 08:38
John P. Christodouleas, M.D., M.P.H., Robert D. Forrest, C.H.P., Christopher G. Ainsley, Ph.D., Zelig Tochner, M.D., Stephen M. Hahn, M.D., and Eli Glatstein, M.D.
N Engl J Med 2011; 364:2334-2341
- Jun 24 Fri 2011 07:03
Patients with ulcer bleeding who have failed endoscopic hemostasis gain relief from transarterial embolization (TAE). The procedure leads to fewer surgeries, has fewer associated complications, and does not increase overall mortality, according to a study published in the May issue of Gastrointestinal Endoscopy.
- Jun 23 Thu 2011 07:12
Aspirin and simvastatin, which have been shown to be beneficial in the treatment of cardiovascular disease, are ineffective at improving functional capacity in patients with pulmonary arterial hypertension (PAH), according to a multicenter study, sponsored by the National Institutes of Health (NIH), presented here at the American Thoracic Society 2011 International Conference.
- Jun 22 Wed 2011 06:32
The following test-and-teach case makes up an educational activity modeled on the interactive grand rounds approach. The questions within the case are designed to test your current (ie, baseline) knowledge. After each question, you will be able to see whether you answered correctly and can then read evidence-based information that supports the most appropriate answer choice. Please note that these questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on material covered in the case.
- Jun 21 Tue 2011 06:01
The US Food and Drug Administration (FDA) approved ezogabine (Potiga, Valeant Pharmaceuticals and GlaxoSmithKline [GSK]) as an add-on medication to treat seizures associated with epilepsy in adults.
- Jun 20 Mon 2011 05:49
During the second and third trimester of pregnancy, sulfonamides and nitrofurantoins may be used as first-line agents for urinary tract and other infections, but in the first trimester, these agents may be used when no alternatives are available, according to a Committee Opinion from the American College of Obstetricians and Gynecologists (ACOG).
- Jun 19 Sun 2011 07:25
The US Food and Drug Administration (FDA) today approved a sterile, injectable gel called Solesta (Oceana Therapeutics) to treat fecal incontinence in patients after other remedies have failed.
- Jun 16 Thu 2011 04:42
- Jun 15 Wed 2011 14:35
荷蘭葛蘭素史克藥廠公司（ GSK ）「安滅菌糖漿用粉劑（ Augmentin for syrup ）」 156m g/5ml ，以及 457 m g/5ml 二項藥品，經食品藥物管理局檢驗結果，確認含有 DIDP (di-"isodecyl" phthalate) 鄰苯二甲酸二異癸酯。為確保民眾用藥安全，食品藥物管理局已要求 GSK 公司將該二產品下架、回收，直至釐清產品含有塑化劑的原因為止。另外，抗生素治療有一定的療程，正在使用「安滅菌糖漿用粉劑」的民眾，建議儘速回診原處方醫師，由醫師依據醫療專業考量，並充份告知民眾用藥訊息，做必要之調整用藥。
- Jun 15 Wed 2011 06:57
- Jun 14 Tue 2011 05:37
The US Food and Drug Administration has issued an alert about medication error reports in which patients were mistakenly given the antipsychotic risperidone (Risperdal, Johnson & Johnson) instead of the dopamine agonist ropinirole (Requip, GlaxoSmithKline) and vice versa.
- Jun 13 Mon 2011 08:53
An FDA review launched in the wake of a controversial 2010 meta-analysis by DrIlke Sipahi (University Hospitals Case Medical Center, Cleveland, OH) et al  suggesting an increased risk of cancer among patients taking angiotensin-receptor blockers (ARBs) has concluded that the drugs do not pose a cancer risk to patients . But reacting to the FDA alert to heartwire , Sipahi said he was disappointed with how the FDA conducted its review and, in particular, its failure to do a patient-level analysis.
- Jun 12 Sun 2011 06:24
Gradual increases in dietary calcium intake above the first quintile in a large female cohort are not associated with further reductions in fracture risk or osteoporosis, according to the results of a prospective longitudinal cohort study reported in the May 24 issue of the BMJ.